Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314752 | 1.00 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL15115908 | 1.00 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL2006418 | 0.97 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL15115938 | 0.97 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL2002883 | 0.92 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL32671991 | 0.92 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL827994 | 0.86 | — | — | |
| SCHEMBL20756261 | 0.86 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL26394048 | 0.86 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL26111928 | 0.86 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137446-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023283373-A1 | 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3059238-B1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-05-27 | — | — | EP | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2014194242-A2 | FLT3 INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014194201-A2 | CDK8 INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014194245-A2 | CDK8 INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-2802330-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106535-A9 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0186087-A1 | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs | Dr. Karl Thomae GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL3 943/4885L3MBTL1 549/4885MBTD1 1575/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | L3MBTL3 1939/4885L3MBTL1 2537/4885MBTD1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.